Vol. 7, Issue 3, Part A (2024)

Methods: The study involved12 male and female patients with various chronic conditions. The participants were selected based on the preset criteria outlined in the patient information. Patients were given Proleevamax™ capsules and instructed to take 4 capsules per day, with or without food for 8 weeks. It was at the patient’s discretion whether it was taken 4 QD or 2 BID.The efficacy of Proleevamax in reducing pain and inflammation was then evaluated. This includes tracking changes in pain scores using the McGill Pain Survey and monitoring the hs-CRP test levels.Patientscompleted the patient information form and the McGill pain survey at the start of therapy, at 30 and at 60 days. Laboratory tests are done at baseline, 4 weeks, and 8 weeks.

Results:(Mean CI 95%) The Proleevamax Clinical trial significantly reduced C-reactive protein levels and decreased pain intensity among participants (with a P value less than 0.05 in the change), with a P value of 0.042. This indicates that Proleevamax™ may be effective in managing chronic pain and inflammation. While the results look encouraging, further studies are recommended to confirm these results.

Conclusion: Proleevamax™ has reduced pain and inflammation in the patients, as demonstrated in the trial. It reduced the C-reactive protein levels and improved pain intensity among patients.